The FDA has introduced a new drug approval pathway for rare diseases where gene editing is the focus. The goal is to cut red tape for tailor-made therapies for patients with rare diseases. These therapies are specially tailored to the individual needs of patients. The new pathway speeds up the approval process so patients can access treatment faster. Gene editing thus acquires a key role in the fight against rare diseases.